Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC.RXRX · Entity 1008 | Chief Scientific Officer | August 17, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RECURSION PHARMACEUTICALS, INC.
Report date August 17, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 1,043,837 |
Reported balance
After 2026-08-17 transaction · row 1
1 source rowRow 1 · 2026-08-17 · Tax withholding · Disposed 26,657 · Balance 1,043,837 F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 18, 2026 21:44 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 26,657 | $3.16 | $84,236.12 |
DisclosureSEC source: 0002006495-26-000012 · wk-form4_1787089466.xml · nonDerivative · entry 1 Hallett David · CIK 0002006495 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,043,837 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| May 15, 2026 Filed May 19, 2026 21:54 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 26,657 | $3.04 | $81,037.28 |
DisclosureSEC source: 0002006495-26-000010 · wk-form4_1779227693.xml · nonDerivative · entry 1 Hallett David · CIK 0002006495 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,070,494 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 17, 2026 Filed Feb 20, 2026 00:30 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 11,908 | $3.49 | $41,558.92 |
DisclosureSEC source: 0001601830-26-000022 · wk-form4_1771547454.xml · nonDerivative · entry 1 Hallett David · CIK 0002006495 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,097,151 F1 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 23:18 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | Tax withholdingClass A Common Stock | 11,400 | $3.98 | $45,372.00 |
DisclosureSEC source: 0001601830-26-000012 · wk-form4_1770765490.xml · nonDerivative · entry 3 Hallett David · CIK 0002006495 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,109,059 F3 · kind: Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 23:18 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 24,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000012 · wk-form4_1770765490.xml · nonDerivative · entry 2 Hallett David · CIK 0002006495 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,120,459 F2 · kind: This RSU vested immediately upon the grant date. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 23:18 UTC | RECURSION PHARMACEUTICALS, INC. RXRX · Entity 1008 | GrantClass A Common Stock | 502,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001601830-26-000012 · wk-form4_1770765490.xml · nonDerivative · entry 1 Hallett David · CIK 0002006495 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,096,205 F1 · kind: This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2026 and every three months thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.